Identification of synthetic pathway for lysophosphatidylserine in activated lymphocytes.

2022 Fiscal Year Final Research Report

• Project/Area Number: 19H03366
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 47030:Pharmaceutical hygiene and biochemistry-related
• Research Institution: The University of Tokyo (2020-2022); Tohoku University (2019)
• Principal Investigator: Aoki Junken 東京大学, 大学院薬学系研究科(薬学部), 教授 (20250219)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: リゾリン脂質 / 免疫 / がん免疫 / GPCR

Outline of Final Research Achievements

This year, the function of LPS1 in anti-tumour immunity was analysed in a murine basal carcinoma model. Mouse colon cancer-derived cells MC38 were subcutaneously injected into the flanks of mice and tumour growth was monitored over time. A significant increase in tumour volume was observed from 10 to 16 days after carcinoma carriage in LPS1-deficient mice compared to wild-type mice. Tumour growth was significantly suppressed in the LPS1 agonist group compared to the solvent group. The number of CD45+ immune cells was also significantly increased in the tumour tissue of the M1-treated group. These results indicate that intrinsic LPS1 signalling exhibits anti-tumour activity. Further mechanistic analysis of the anti-tumour effect of LPS1 signalling will be carried out in the future.

Free Research Field

免疫、がん免疫

Academic Significance and Societal Importance of the Research Achievements

がん免疫を高める、免疫チェックポイント療法が期待されている。本研究の成果は、従来の免疫チェックポイント療法の標的とは全く異なるGPCRを標的とした抗がん剤開発が可能であることを強く示唆する。今後、化合物、抗体等を用い、LPS1/GPR34を標的とした抗がん剤開発が加速されることが期待される。